Q-omics provides the consensus-scored IGLV11-55 profile across patient tissues and cancer cell-line models. IGLV11-55 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IGLV11-55 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, IGLV11-55 RNA expression shows 6,526 significant pathway-activity associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, BRCA, and HNSC as cancer lineages where IGLV11-55 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLV11-55 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLV11-55 survival associations across molecular data types. IGLV11-55 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLV11-55 RNA expression–survival associations across cancer types. High IGLV11-55 expression shows unfavorable associations in UVM and LIHC, but favorable associations in HNSC, SKCM, ESCA and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IGLV11-55 RNA expression.
This table summarizes IGLV11-55 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IGLV11-55. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLV11-55 shows lower tumor expression in BRCA and higher tumor expression in LUAD and PRAD. The BRCA box plot shows higher IGLV11-55 RNA expression in normal versus tumor tissue (log2 FC = −0.119, t-test p = .008).
This table shows molecular features associated with IGLV11-55 in patient tissues and cancer cell lines. In patient samples, IGLV11-55 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
